Header Image for Intuniv vs Ritalin

Intuniv vs Ritalin

Listen to the article instead of reading through it.
0:00

Overview

Intuniv Overview

Ritalin Overview

Comparative Analysis

Intuniv Prescription Information

Ritalin Prescription Information

Intuniv Side Effects

Ritalin Side Effects

Safety Information

Cost Analysis

Market Analysis

Conclusion

Introduction

For patients with Attention Deficit Hyperactivity Disorder (ADHD), certain drugs that influence the levels of neurotransmitters in the brain can help manage symptoms and improve focus. Intuniv and Ritalin are two such medications often prescribed for ADHD. They each impact different neurotransmitters in the brain, but both have effects on improving attention span and impulse control. Intuniv is classified as a selective alpha-2A adrenergic receptor agonist, primarily affecting norepinephrine levels to provide a calming effect. On the other hand, Ritalin is a central nervous system stimulant known as a dopamine reuptake inhibitor, which increases availability of dopamine to better maintain mental focus and attentiveness.

Intuniv vs Ritalin Side By Side

AttributeIntunivRitalin
Brand NameIntunivRitalin
ContraindicationsShould not be taken with, or shortly after, monoamine oxidase inhibitors (MAOIs).Should not be taken with, or shortly after, monoamine oxidase inhibitors (MAOIs).
CostFor brand name: $260 to $280 for 30 tablets of 1 mg. For generic (guanfacine ER): starts at about $0.87 per day.For brand name: $470–$570 for 100 capsules of 10 mg. For generic (methylphenidate): costs range between about $.25 and just over a dollar per day.
Generic NameGuanfacineMethylphenidate
Most Serious Side EffectSigns of heart issues such as chest pain, slow or irregular heartbeat; severe allergic reactions.Circulation problems, heart issues, severe allergic reactions.
Severe Drug InteractionsMonoamine oxidase inhibitors (MAOIs).Monoamine oxidase inhibitors (MAOIs).
Typical Dose1–4 mg/day, starting at 1 mg/day.5–20 mg/day, up to a maximum of 60 mg/day.

What is Intuniv?

Guanfacine (the generic name for Intuniv) is a non-stimulant medication first approved by the FDA in 2009. It was originally developed as a blood pressure medication but has since been found to be effective in treating ADHD. Intuniv works differently than traditional stimulant medications; it works by stimulating receptors in the prefrontal cortex of the brain, enhancing its ability to ignore irrelevant distractions and help with impulse control.

On the other hand, Methylphenidate (the generic name for Ritalin) is one of the most commonly used medications for ADHD treatment. First approved by FDA in 1955, it belongs to a class of drugs known as central nervous system (CNS) stimulants. Ritalin increases dopamine levels within your brain cells, improving attention and focus.

When considering side effects, Guanfacine tends to have fewer and less severe side effects compared with Methylphenidate due to their different mechanisms of action. Side effects from Guanfacine can include drowsiness or fatigue while methylphenidate may cause increased heart rate or nervousness.

What conditions is Intuniv approved to treat?

Intuniv is approved for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in pediatric patients:

  • It's used as a monotherapy or adjunctive therapy to stimulant medications.
  • Can be prescribed to children aged 6 to 17 years old.

On the other hand, Ritalin is also approved for treating ADHD and additionally, narcolepsy:

  • It can be used by both adults and children aged 6 years and older.
  • Its usage extends beyond ADHD to treat sleep disorders like narcolepsy.

How does Intuniv help with these illnesses?

Intuniv works to manage symptoms of Attention Deficit Hyperactivity Disorder (ADHD) by stimulating receptors in the prefrontal cortex of the brain known as alpha-2A adrenergic receptors. This results in increased inhibition of nerve impulses, leading to reduced hyperactivity and improved impulse control. Neurotransmitters such as norepinephrine play a vital role in attention, impulsivity, and activity levels within the body and brain. It is thought that individuals with ADHD have an imbalance or improper functioning of these neurotransmitters. Therefore, by stimulating alpha-2A adrenergic receptors, Intuniv can help to regulate this balance and limit the negative effects of ADHD helping patients manage their condition better.

What is Ritalin?

Ritalin is a brand name for methylphenidate, which is a central nervous system stimulant. It works by increasing the levels of dopamine and norepinephrine in the brain by reducing their reabsorption, similar to how bupropion operates within the NDRI class of drugs. In addition, Ritalin also inhibits monoamine oxidase (MAO), an enzyme that breaks down excess tyramine in the body. Methylphenidate was first approved by the FDA in 1955.

Unlike Intuniv which focuses on managing symptoms through alpha-2a adrenergic receptor agonism, Ritalin doesn't rely on this mechanism of action. This means that its side-effect profile differs from that of non-stimulants like Intuniv; it does not usually induce sedation and has different cardiovascular effects.

The increase in dopamine can be beneficial for treating conditions such as attention deficit hyperactivity disorder (ADHD) and narcolepsy where focus and alertness are affected—making it a commonly prescribed medication especially among patients who may not respond well to non-stimulant drugs such as Intuniv.

What conditions is Ritalin approved to treat?

Ritalin, a well-known stimulant medication, is approved by the FDA for treating conditions like:

  • Attention Deficit Hyperactivity Disorder (ADHD) in both adults and children
  • Narcolepsy, to help manage excessive daytime sleepiness.

How does Ritalin help with these illnesses?

Dopamine is a neurotransmitter that plays a critical role in the way our brain controls our movements and rewards behaviors, affecting mood, focus, attention, and learning. Ritalin works by increasing the levels of dopamine available in the brain, thereby improving symptoms associated with ADHD such as impulsivity, hyperactivity and lack of concentration. Its action on norepinephrine might also contribute to its efficacy. Unlike Intuniv which acts on alpha-2 adrenergic receptors to lower blood pressure and heart rate – thus reducing hyperactivity – Ritalin directly stimulates central nervous system activity. This makes it more effective for patients who do not respond adequately to non-stimulant medications like Intuniv or when combined treatment is required.

How effective are both Intuniv and Ritalin?

Both guanfacine (Intuniv) and methylphenidate (Ritalin) have extensive histories of success in treating patients with attention-deficit/hyperactivity disorder (ADHD), although they were approved by the FDA nearly 30 years apart. Since they act on different neurochemical systems, they may be prescribed under different circumstances.

The effectiveness of Intuniv and Ritalin in managing ADHD symptoms was studied directly in a double-blind clinical trial; both drugs demonstrated similar efficacy and safety profiles. In this study, there was no significant difference between the two medications when various metrics to measure their effectiveness at alleviating ADHD symptoms were compared.

A review focusing on guanfacine confirmed that it is effective from the first week of treatment onwards, has a side-effect profile favorable over many other treatments for ADHD, and that it's well-tolerated even among children who might be sensitive to stimulant medication effects. The same review also noted how Intuniv is becoming one of the more frequently prescribed non-stimulants for treating ADHD due its less harsh side-effects compared to traditional stimulant medications such as Ritalin or Adderall.

A 2016 meta-analysis indicated that while Ritalin seems to be more effective than placebo in treating ADHD, its efficacy appears to be similar to other common stimulant medications used for this purpose. However, despite being considered a 'first-line' treatment option alongside other stimulant drugs like Adderall or Concerta, there are concerns around potential abuse of these substances given their psychoactive properties - an issue not associated with Intuniv use.

As such due its unique pharmacology which does not involve stimulation but rather modulation of certain brain receptors related to impulse control and working memory tasks - guanfacine could potentially serve as optimal treatment for those individuals who did not respond well or had adverse reactions towards standard stimulant therapy options often favored initially during management/treatment planning strategies aimed at tackling troublesome manifestations accompanying diagnosis made under umbrella category encompassing diverse range conditions collectively known today as "ADHD".

abstract image of a researcher studying a bottle of drug.

Find Top Clinical Trials

Choose from over 30,000 active clinical trials.

At what dose is Intuniv typically prescribed?

Oral dosages of Intuniv for the treatment of ADHD range from 1–4 mg/day. It's recommended to start at a dosage of 1 mg/day, particularly in children and adolescents. If there is no response after a few weeks, the dosage can be gradually increased under medical supervision. However, it should not exceed the maximum daily dose of 4 mg/day. In comparison, Ritalin is typically started at a lower dose (5-20mg) and adjusted as necessary which could be twice or thrice daily due to its shorter half-life compared to Intuniv. The maximum recommended daily dosage for Ritalin is usually restricted to 60mg.

At what dose is Ritalin typically prescribed?

Ritalin therapy is typically initiated at a dosage of 5–20 mg/day, administered in two or three doses throughout the day. The dosage can then be progressively increased, under medical supervision, to a maximum dose of 60 mg/day divided into separate doses given two or three times daily. It's important to space out these doses evenly throughout the day — for instance, upon waking and then four to six hours apart. If there isn't an appropriate response after several weeks at this higher dosage, it may be necessary to re-evaluate the medication plan.

What are the most common side effects for Intuniv?

Common side effects of Intuniv, also known as Guanfacine, may include:

  • Drowsiness or fatigue
  • Dry mouth
  • Stomach pain
  • Nausea and vomiting
  • Constipation or diarrhea
  • Slow heart rate
  • Low blood pressure, which can cause dizziness or fainting if you stand up too fast.

In contrast to Ritalin (methylphenidate), Intuniv is not a stimulant and doesn't typically cause anxiety, nervousness, insomnia or jitters. However, it may affect libido in some patients.

Always consult with your health care provider for any adverse effects experienced while on medication.

abstract image of a patient experiencing side effect

Are there any potential serious side effects for Intuniv?

When using Intuniv, it is important to be aware of potential serious side effects, which may include:

  • Signs of heart issues such as chest pain, slow or irregular heartbeat
  • Severe allergic reactions: rash, itching/swelling (especially of the face/tongue/throat), severe dizziness, trouble breathing.
  • Symptoms related to low blood pressure including dizziness and fainting
  • Mental/mood changes (such as irritability, aggression)

While taking Intuniv you also need to watch out for signs that your body might not be responding well to this medication:

  • Fatigue or weakness
  • Dehydration symptoms - extreme thirstiness and dry mouth.

If you experience any of these symptoms while taking Intuniv, seek medical attention immediately. In contrast Ritalin has different side effects like nervousness and insomnia therefore when choosing between the two medications one needs to consider their personal health conditions and consult with a healthcare provider.

What are the most common side effects for Ritalin?

Ritalin, a common medication used to treat ADHD, has its own list of potential side effects that are important to consider:

  • Dry mouth or unpleasant taste in the mouth
  • Nausea and stomach pain
  • Loss of appetite which may lead to weight loss
  • Sleep problems including insomnia
  • Mild sweating and feeling nervous or jittery
  • Increased heart rate
  • Dizziness and headaches
  • Minor skin rash -Increased blood pressure leading to headache, blurred vision, buzzing in your ears, anxiety. -Muscle twitches (tics) or changes in behavior

Are there any potential serious side effects for Ritalin?

Ritalin, a commonly prescribed medication for ADHD, can occasionally lead to more serious side effects. Be aware of the following potential symptoms:

  • An allergic reaction which may include hives or itching, fever, swollen glands or swelling in your face and throat
  • Changes in mood or behavior that might manifest as aggression, paranoia or new behavior problems
  • Circulation problems such as numbness, pain, cold feeling in fingers/toes; skin color changes (from pale to blue or red); unexplained wounds; unusual tiredness
  • Any sign indicative of heart issues like chest pain/discomfort/pressure/tightness/heavy feeling spreading to jaw/left arm; rapid heartbeat/pulse; short of breath especially with mild exertion
  • Increased blood pressure - severe headache/blurred vision/pounding neck ears/noise/buzzing sounds.

If you experience any of these symptoms while taking Ritalin, seek medical attention immediately.

Contraindications for Intuniv and Ritalin?

Both Intuniv and Ritalin, like many other medications used for attention deficit hyperactivity disorder (ADHD), can sometimes worsen symptoms. If you notice your ADHD symptoms worsening or an increase in unusual behavior or thoughts, seek immediate medical help.

Neither Intuniv nor Ritalin should be taken if you are taking, or have recently taken monoamine oxidase inhibitors (MAOIs). Always inform your physician about the medications you are currently using; MAOIs need a period of approximately 2 weeks to clear from the system before starting treatment with either Intuniv or Ritalin to prevent dangerous interactions.

How much do Intuniv and Ritalin cost?

For the brand name versions of these drugs:

  • The price for 30 tablets of Intuniv (1 mg) ranges from $260 to $280, which works out to roughly $8.60–$9.30/day, depending on your dose.
  • The cost for 100 capsules of Ritalin (10 mg) averages around $470–$570, working out to approximately $4.70-$5.70/day.

Thus, if you are in the higher dosage range for Intuniv (i.e., 4 mg/day or higher), then brand-name Ritalin is less expensive on a per-day treatment basis. However, remember that cost should not be a primary consideration in determining which of these ADHD medications is right for you.

For the generic versions of Intuniv (guanfacine ER) and Ritalin (methylphenidate), costs are significantly lower:

  • Guanfacine ER tablets come in packs ranging from 30 to 90 with approximate costs starting at about $0.87 per day for dosages from as low as .5mg up to the highest recommended daily amount.
  • Methylphenidate comes available in quantities varying from 15 up to several hundred pills with costs ranging between about $.25 and just over a dollar per day based on typical dosage amounts.

Do keep in mind that prices can vary greatly by pharmacy and location so it's always good practice to explore different options before making your final purchase decision.

Popularity of Intuniv and Ritalin

Guafacine, in its extended-release form known as Intuniv, has been increasingly prescribed for the management of attention deficit hyperactivity disorder (ADHD) within the US. In 2020, approximately 1.5 million prescriptions were filled for this non-stimulant option. Guanfacine only accounted for around 3% of ADHD medication prescriptions in that year but it is considered a valuable alternative particularly for patients who do not respond well to or cannot tolerate stimulants. The use of guanfacine has been moderately increasing since its introduction.

Methylphenidate, including brand versions such as Ritalin, was prescribed to roughly 15 million people in the USA during 2020. Methylphenidate accounts for just over 30% of all ADHD prescriptions and remains one of the most commonly prescribed stimulant medications used to treat ADHD symptoms. Its prevalence has been relatively stable over recent years despite new entries into the treatment landscape.

Conclusion

Both Intuniv (guanfacine) and Ritalin (methylphenidate) have been widely used in the treatment of Attention Deficit Hyperactivity Disorder (ADHD), supported by numerous clinical studies indicating their effectiveness over placebo treatments. Occasionally, these drugs may be combined under careful physician supervision, despite having differing mechanisms of action. Intuniv works by stimulating receptors in the brain associated with impulse control while Ritalin primarily increases dopamine levels to help improve focus and attention.

Intuniv is often considered as an alternative or adjuvant therapy to stimulant ADHD medications like Ritalin especially for patients who do not respond well to them or need to avoid common side effects such as insomnia and loss of appetite.

Both drugs are available in generic form which represents significant cost savings particularly for patients paying out-of-pocket. Both Intuniv and Ritalin might require an adjustment period with benefits becoming noticeable over time rather than immediately upon starting treatment.

The side effect profile between the two drugs varies significantly due to their different modes of action; both are generally well-tolerated but Ritalin has a higher propensity for causing restlessness, increased heart rate, and decreased appetite compared to Intuniv. For both drugs, patients should closely monitor any changes especially at the start of treatment, seeking immediate medical assistance if they experience severe reactions like chest pain, hallucinations or suicidal thoughts.

Refrences

  • Challman, T. D., & Lipsky, J. J. (2000, July). Methylphenidate: Its Pharmacology and Uses. Mayo Clinic Proceedings. Elsevier BV.http://doi.org/10.4065/75.7.711
  • Wilens, T. E., Bukstein, O., Brams, M., Cutler, A. J., Childress, A., Rugino, T., … Youcha, S. (2012, January). A Controlled Trial of Extended-Release Guanfacine and Psychostimulants for Attention-Deficit/Hyperactivity Disorder. Journal of the American Academy of Child & Adolescent Psychiatry. Elsevier BV.http://doi.org/10.1016/j.jaac.2011.10.012
  • Connor, D. F., Findling, R. L., Kollins, S. H., Sallee, F., López, F. A., Lyne, A., & Tremblay, G. (2010, July). Effects of Guanfacine Extended Release on Oppositional Symptoms in Children Aged 6–12 Years with Attention-Deficit Hyperactivity Disorder and Oppositional Symptoms. CNS Drugs. Springer Science and Business Media LLC.http://doi.org/10.2165/11537790-000000000-00000
  • Carpentier, P. J., De Jong, C. A. J., Dijkstra, B. A. G., Verbrugge, C. A. G., & Krabbe, P. F. M. (2005, November 23). A controlled trial of methylphenidate in adults with attention deficit/hyperactivity disorder and substance use disorders. Addiction. Wiley.http://doi.org/10.1111/j.1360-0443.2005.01272.x
  • May, D. E., & Kratochvil, C. J. (2010, January). Attention-Deficit Hyperactivity Disorder. Drugs. Springer Science and Business Media LLC.http://doi.org/10.2165/11530540-000000000-00000
  • Greenhill, L. L., Pliszka, S., & Dulcan, M. K. (2002, February). Practice Parameter for the Use of Stimulant Medications in the Treatment of Children, Adolescents, and Adults. Journal of the American Academy of Child & Adolescent Psychiatry. Elsevier BV.http://doi.org/10.1097/00004583-200202001-00003